ArticleIranian journal of basic medical sciences2014
Seroprevalence of anti-Helicobacter pylori and anti-cytotoxin-associated gene A antibodies among healthy individuals in center of Iran.
Article in Iranian journal of basic medical sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 5 citations in OpenAlex.
- Eradication therapy may decrease the risk of immune thrombocytopenia after Helicobacter pylori infection: a retrospective cohort study in Taiwan.BMC gastroenterology · 2023Article
- Associations between seroprevalence ofThe Journal of international medical research · 2021Article
- Prevalence ofMedicina (Kaunas, Lithuania) · 2020Review
- The Relation of Cytotoxin-Associated Gene-A Seropositivity with Vitamin B12 Deficiency inBioMed research international · 2019Article
- Helicobacter Pylori Infection Among Patients Attending Bule Hora University Teaching Hospital, Ethiopia: Five-Year Trends.Health services research and managerial epidemiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesHelicobacter pylori infection occurs worldwide, but the prevalence of this infection varies greatly among different countries and population groups. The aim of this study was to determine the seroprevalence of anti-Helicobacter pylori and anti-cytotoxin-associated gene A (CagA) antibodies in asymptomatic healthy population in the center of Iran and to investigate the relation with different parameters. MATERIALS AND
methodsTotally, 525 individuals aged 17-60 years were enrolled in study. The serum samples of participants were tested for anti-H. pylori IgG and anti-CagA IgG by enzyme-linked immunosorbent method (ELISA). ABO blood grouping was also done by hemagglutination test.
resultsThe seroprevalence of anti-H. pylori IgG was 74.2% and their rates increased with age. The seroprevalence of anti-H. pylori IgG was higher in males (74.6%) than in females (71.6%). There was statistically inverse association between H. pylori infection and education level (P=0.04) and marital status (P=0.000). The most prevalent blood group was type AB with positive Rh-phenotype (82.4%). In H. pylori infected individuals the seroprevalence of anti-CagA antibody was 46.9%. The seroprevalence of anti-CagA IgG was in males 48.6% and in females 31.6%. There was no statistically significant association between anti-CagA IgG positivity and age, occupation, socioeconomic status, ABO blood groups and Rh status.
conclusionThese results showed that H. pylori infection was common in the asymptomatic individuals. Almost half of the infected individuals acquire CagA-positive strains of H. pylori. Moreover, it seems that males are more susceptible to infection with CagA-positive strains compared to females.
Indexed as
Identifiers
25422745PMC4240786W1923392433What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.